Comparison
AOD-9604 vs. MGF (Mechano Growth Factor)
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Growth
Growth
CAS no.
221231-10-3
12-Aminosäuren-C-terminales E-Domänen-Peptid (Sequenz nicht standardisiert)
Molecular weight
1815.09 g/mol
2867.2 g/mol
Half-life
0.4 h
0.1 h
Sequence
Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-PheYQPPSTNKNTKSQRRKGSTFEERKMechanism of action
AOD-9604
AOD-9604 corresponds to the C-terminal fragment 176-191 of human growth hormone with an additional N-terminal tyrosine. In animal models, lipolytic effects without GH-typical adverse events (insulin resistance, IGF-1 rise) were reported. In humans, these preclinical findings did not translate into clinically relevant weight reduction in the four phase-2 obesity trials. The exact human mechanism of action is unclear; the GH receptor is not classically activated by the fragment.
MGF (Mechano Growth Factor)
The IGF-1 gene produces multiple isoforms by alternative splicing. IGF-1Ec is upregulated after mechanical muscle loading; the C-terminal E-domain is cleaved from the mature IGF-1 protein and appears to have independent effects on satellite cells. The exact receptor binding of the E-domain is not established; a classical IGF-1R effect is unlikely since mature IGF-1 is responsible. In cell-culture studies, stimulation of myoblast proliferation and differentiation has been observed.
Evidence base
Highest evidence
Human RCT
Animal model
Studies
3
4
of which in humans
2
0
Effects recorded
3
3
Open conflicts
1
0
Documented adverse events
1
1